
Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Description
Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Sjogren's Syndrome therapeutics.
Key Highlights
GlobalData’s Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Sjogren's Syndrome therapeutics.
Key Highlights
- In 2022, there will be more than 3.9 million diagnosed prevalence cases of Sjogren’s Syndrome across 16 pharmaceutical markets.
- No FDA-approved marketed drugs have been available for Sjogren’s Syndrome in the last two decades.
- The Sjogren’s Syndrome pipeline consists of 49 pharmaceuticals spanning all stages of development, with approximately 36% of drugs in mid- to late-stage development.
- Commercial sponsors dominate clinical trial development in Sjogren’s Syndrome, with the US emerging as the key countries for conducting trials in Sjogren’s Syndrome.
- Deals involving partnerships were the most common type of deals globally.
- Therapeutic options for Sjogren’s Syndrome patients continue to be limited as only two new product approvals are expected within the next 5 years.
GlobalData’s Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Sjogren's Syndrome market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Sjogren's Syndrome market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
59 Pages
- Report Scope
- Abbreviations
- Key Findings
- Disease Overview
- Epidemiology Overview: Total Prevalent Cases of SS in 2022
- Treatment Guidelines
- Marketed Drugs - Leading Marketed Drugs in SS
- Pipeline Drugs Overview - Phase II Pipeline Drugs in SS
- Pipeline Drugs - Overview by Development Stage
- Pipeline Drugs - Overview by Molecule Type
- Pipeline Drugs - Overview by Mechanism of Action
- Pipeline Drugs - Overview by Route of Administration
- Pipeline Drugs - Drug-Specific PTSRs and LoA in SS
- Pipeline Drugs - PTSRs and LoA in Immunology and in SS
- Clinical Trials in SS - Historical Overview
- Clinical Trials in SS - Overview by Phase
- Clinical Trials in SS - Overview by Status
- Clinical Trials in SS - Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in SS - Trials with a Virtual Component
- Clinical Trials in SS - Geographic Overview
- Clinical Trials in SS - Single-Country and Multinational Trials by Region
- Clinical Trials in SS - Top 20 Sponsors with Breakdown by Phase
- Clinical Trials in SS - Top 20 Sponsors with Breakdown by Status
- Clinical Trials in SS - Overview by Endpoint Status
- Clinical Trials in SS - Overview by Race and Ethnicity
- Clinical Trials in SS - Enrollment Data
- Clinical Trials in SS - Overview of Sites by Geography
- Clinical Trials in SS - Top 20 Countries for Trial Sites
- Clinical Trials in SS - Top 20 Sites Globally
- Clinical Trials - Feasibility Analysis: Geography Overview
- Clinical Trials - Feasibility Analysis: Benchmark Models for SS
- Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in SS by Region
- Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in SS
- Commercial Assessment - Key Market Players in SS
- Future Market Catalysts - Upcoming Market Catalysts in SS
- Methodology
- Methodology - PTSR and LoA Analysis
- About the Authors
- Contact Us - A Global Network of Offices
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.